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After 40 years, new medicine for combating TBOn December 31, 2012, the FDA approved the first new
tuberculosis drug in four decades. SIRTUROTM (bedaquiline)
was approved on the basis of phase two efficacy and safety
data to treat multidrug-resistant tuberculosis (MDR-TB).
Bedaquiline is manufactured by Johnson and Johnson and is
the first medication exclusively manufactured for MDR-TB [1].
An estimated 630,000 cases of MDR-TB (range 460,000–
790,000) were reported throughout the world in 2011. Of all
tuberculosis cases, 3.7% of new cases and 20% of previously
treated cases are estimated to be MDR-TB. A disproportion-
ately high number of MDR-TB cases are in India, China, the
Russian Federation and South Africa, accounting for 60% of
the MDR-TB prevalence in the world. In 84 countries, there
have been reports of a higher resistance category known as
extensively drug-resistant TB, or XDR-TB, making up around
9.0% of the average proportion of MDR-TB cases [2].
Bedaquiline is a diarylquinoline component with a new
mechanism of action against Mycobacterium tuberculosis
(MTB) which specifically inhibits mycobacterial adenosine triphos-
phate (ATP) synthase [3,4]. It is suggested that bedaquiline forms
a wedge between the two rotating subunits of ATP synthase by
interacting with the residues W15 and F50 of e and the c-ring,
respectively [5].
Bedaquiline inhibits drug-sensitive and drug-resistant
MTB. Also, treatment courses including bedaquiline are likely
to shorten the duration of TB therapy [6]. Further, bedaquiline
has different extracellular and intracellular effects which are
believed to enhance its effectiveness. The bactericidal activi-
ties of bedaquiline in a liquid culture medium started with a
bacteriostatic phase lasting about 7 days and then continued
with a dose-related bactericidal phase. However, the intracel-
lular activity of bedaquiline is clearly greater than its extracel-
lular activity mainly because the preliminary static phase was
shorter or absent [7].
Bedaquiline may also impact current treatment ap-
proaches for latent TB infection (LTBI). This is especially true
for the LTBI treatment for close contacts of patients with drug
resistant TB. There is a lack of a practical and standard ap-
proach to LTBI treatment among contacts of patients with
MDR/XDR-TB (DR-LTBI). In a murine model, bedaquiline
demonstrated bactericidal activity against dormant (non-rep-
licating) tubercle bacilli with substantial sterilizing activity
and may enable treatment of DR-LTBI in 3–4 months [8].
Preliminary data for bedaquiline is encouraging for clini-
cians who treat TB infections. Given the increasing commontreatment challenges of evolving resistance patterns coupled
with a lack of major developments in TB treatment regimens,
the development of this new agent has left many optimistic.
Future use of bedaquiline is believed to shorten treatment
courses and improve cure rates of MDR-TB and perhaps
XDR-TB. Currently, treatment of drug-resistant tuberculosis
requires second-line anti-TB drugs that are less effective with
high adverse reaction profiles, and treatment courses can ex-
ceed as long as 2 years. Therapy for MDR-TB represents a ma-
jor driver of healthcare and public health resources in that
treatment courses are long and costly, adverse events are
common, and failure rates as well as relapses are common [9].
FDA approval of bedaquiline was based on extremely
encouraging data reported from two phase II clinical trials.
The first study was a multicenter, placebo-controlled study
of 47 patients with a confirmed diagnosis of MDR-TB with
an 8-week follow-up [10]. Of the 47 patients evaluated, 23
were randomly allocated to the case group with bedaquiline
and 24 received a placebo. Patient medication adherence
was at least 97% in both groups. Patients treated with bedaq-
uiline outperformed in both clinical outcomes in non-clinical
measures. For example, conversion from positive to negative
sputum cultures occurred much more rapidly in the bedaqui-
line arm. The conversion rate to a negative culture was 48%
and 9% in the case and placebo group, respectively. There
were no premature discontinuations due to adverse events
associatedwith treatment in both groups, and side-effect pro-
files were similar in the two treatment groups, including nau-
sea, joint pain, and headache. This study also established
diarylquinolines as a new drug class with safe and effective
profiles in humans as well as animals. Recently, a 2-year fol-
low-up of this study was published concluding that bedaqui-
line might improve multidrug-resistant tuberculosis
treatment by more rapid conversion of positive sputum to
negative and preventing acquired resistance to other admin-
istered anti-TB agents [11].
The second trial was presented at the 43rd Union World
Conference on Lung Health in Kuala Lumpur 2012 [12]. A total
of 161 patients were included in the study. The patients with
newly confirmed MDR-TB were randomly divided into the
bedaquiline group (79 subjects) and the placebo group (81 sub-
jects). The bedaquiline group received bedaquiline 400 mg by
mouth daily for 14 days and then 200 mg orally three times a
week. Both groups received a preferred 5-drug background
regimen consisting of: Ethionamide, Pyrazinamide, Ofloxacin,
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showed more QT prolongation in the bedaquiline group than
placebo, with no reports of serious cardiac arrhythmias such
as ventricular tachycardia or Torsade de pointes. The bedaq-
uiline group had a faster culture conversion to negative with-
in 24 weeks and a higher sputum conversion rate (79% vs.
58%) at the end of 24 weeks.
Despite these promising results, the overall benefit of
bedaquiline remains unproven. First, bedaquiline metabo-
lized by a Cytochrome P-450 system (CYP3A4) is strongly
induced by Rifampin. Therefore, bedaquiline is not recom-
mended to be co-administered with agents in the Rifamycin
family, which remains a common agent for TB treatment.
Also, the manufacturer advises that co-administration with
strong systemic CYP3A4 inhibitors for more than 14 consecu-
tive days should be avoided. More information is available at
the Johnson and Johnson website [13]. Thus, it would not be
suitable for drug-sensitive TB. Second, bedaquiline prolongs
the QT interval in electrocardiogram (ECG) [14]. Consequently,
co-administration of any drug that increases the QT interval
should be avoided.
Third, the manufacturer reports an increased risk of death
associated with the bedaquiline treatment group (11.4%) com-
paredwith the placebo treatment group (2.5%) in one placebo-
controlled trial. Although the reason for increasing mortality
in the bedaquiline group is unclear, it should be advised that
bedaquiline use should be limited to those patients with
whom an effective treatment regimen cannot otherwise be
provided.
Clearly, further studies are required to determine the role
of bedaquiline in TB management. As a condition of submis-
sion under accelerated FDA approval, Johnson and Johnson is
obligated to conduct a confirmatory phase III study, which is
planned to begin soon. In this phase III study, there is hope
that some of the questions regarding both safety and efficacy
will be answered. First and foremost, the potential risk of
mortality needs to be well understood before bedaquiline
can have any role in patient care. Also, research needs to
establish a well-proven combination therapy regimen for
the treatment of MDR-TB, and the activity of bedaquiline in
XDR-TB also needs to be studied. Human studies are needed
to show the role of bedaquiline in DR-LTBI. Finally, further
analysis is needed to understand the implications of bedaqui-
line in MDR-TB and HIV co-infection.
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